Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585410 · ClinicalTrials.gov registry record · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
A Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
- 20
- Study locations
NCT06585410 is a Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 369 participants, above the 95-participant average among 4 other Cutaneous Squamous Cell Carcinoma (CSCC) trials with a reported enrollment target (288% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06585410, a Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works
Conditions Studied
Interventions
- DRUG Cemiplimab
- PROCEDURE Standard of care
Study Locations (20)
Arizona
- Medical Dermatology Specialists - Phoenix
- Mayo Clinic - Arizona - Scottsdale
- University of Arizona Cancer Center - Tucson
California
- UC San Diego Moores Cancer Center - La Jolla
- Stanford University - Redwood City
- Peak Dermatology, Aesthetics and Wellness - Visalia
Florida
- Life Clinical Trials - Coral Springs
- Dermatology Associates of the Palm Beaches - Delray Beach
- University of South Florida - St. Petersburg
Illinois
- University of Chicago Medical Center - Chicago
- Oak Dermatology - Naperville
Massachusetts
- Northeast Dermatology Associates - Beverly
- Dana-Farber Cancer Institute - Boston
Michigan
- MyMichigan Dermatologic Oncology - Midland
- Somerset Skin Centre - Troy
Arkansas
- Arkansas Research Trials - North Little Rock
District of Columbia
- George Washington University Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2030-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585410
The ClinicalTrials.gov registry entry for NCT06585410 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 4 other Cutaneous Squamous Cell Carcinoma (CSCC) trials with a reported enrollment target (288% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma (CSCC) appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06585410 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06585410 about?
NCT06585410 is a clinical study titled "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma". This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface ...
What is the current status of trial NCT06585410?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2025-01-02. Estimated completion is 2030-05-03.
What conditions does trial NCT06585410 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma (CSCC).
What interventions are being tested in trial NCT06585410?
The interventions under investigation include: Cemiplimab (DRUG), Standard of care (PROCEDURE).
Who is sponsoring clinical trial NCT06585410?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585410 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma (CSCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
RECRUITING · Early Phase 1
-
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
RECRUITING
-
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.